Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04555096 · ClinicalTrials.gov registry record · Phase 2
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
A Phase 2 study, sponsored by Galera Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04555096 is a Phase 2 study that was terminated before completion, run by Galera Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT04555096, a Phase 2 study, was terminated before completion, sponsored by Galera Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
A Trial of GC4419 in Patients with Critical Illness due to COVID-19
Interventions
- DRUG Placebo
- DRUG GC4419
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04555096
The ClinicalTrials.gov registry entry for NCT04555096 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galera Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04555096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04555096 about?
NCT04555096 is a clinical study titled "A Trial of GC4419 in Patients With Critical Illness Due to COVID-19". A Trial of GC4419 in Patients with Critical Illness due to COVID-19
What is the current status of trial NCT04555096?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2020-09-09. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT04555096?
The interventions under investigation include: Placebo (DRUG), GC4419 (DRUG).
Who is sponsoring clinical trial NCT04555096?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.